Title Interferencija biotina u imunokemijskim analizama
Title (english) Biotin interference in clinical immunoassays
Author Bruno Salopek
Mentor Dunja Rogić (mentor)
Committee member Dunja Rogić (predsjednik povjerenstva)
Committee member Lidija Bach-Rojecky (član povjerenstva)
Committee member Saša Kralik-Oguić (član povjerenstva)
Granter University of Zagreb Faculty of Pharmacy and Biochemistry (Department of medical biochemistry and haematology) Zagreb
Defense date and country 2019-09-12, Croatia
Scientific / art field, discipline and subdiscipline BIOMEDICINE AND HEALTHCARE Pharmacy
Abstract S obzirom na činjenicu da se biotin sve više koristi u multivitaminskim dodatcima, preparatima na osnovi biotina za kožu, kosu i
nokte te kao lijek za liječenje progresivne multiple skleroze djelatnici medicinskobiokemijskih laboratorija i liječnici trebaju biti
svjesni da biotin može utjecati na rezultate u imunokemijskim analizama koje rabe biotin i interakciju biotin – streptavidin u svojem
formatu. Biotin utječe na rezultate u imunokemijskim analizama na dva načina: u kompetitivnom formatu testa prouzrokuje lažno
pozitivne rezultate, a u sendvič-formatu testa prouzrokuje lažno snižene rezultate. Cilj je ovoga rada bio istražiti utjecaj biotina na
pet analita (vitamin D, CEA, CA 19-9, AFP i vitamin B12 ) kad se uzima u dozi od 5 mg. Istraživanje je osmišljeno tako da se dva
puta mjere koncentracije analita u serumu (prije uzimanja biotina i tri sata nakon uzimanja biotina). U istraživanju je sudjelovalo 12
ispitanika (šest muških i šest ženskih) i koncentracije biotina određivane su na imunokemijskom analizatoru Cobas e601 koristeći se
imunokemijskom metodom elektrokemiluminscencije (ECLIA). Istraživanjem je dokazano da biotin u dozi od 5 mg ne interferira
niti u jednom od 12 ispitanika kod CEA, CA 19-9, AFP i vitamina B12, a kod vitamina D interferira u jednom od 12 ispitanika. Ako
se biotin uzima u puno većim dozama od 5 mg (terapijske doze za multiplu sklerozu iznose od 100 do 300 mg) on će tada interferirati
kod svih analita. Da bi se izbjegle interferencije biotina klinički laboratoriji rabe četiri načina. To su korištenje platformom za
ispitivanje koja se ne koristi biotinom u osmišljavanju ispitivanja, serijsko razrjeđivanje uzorka, čekanje dovoljno vremena da se
biotin ukloni iz tijela i predtretman uzorka mikročesticama obloženima streptavidinom za uklanjanje biotina prisutnog u uzorcima.
Djelatnici kliničkih laboratorija trebaju biti oprezni kod interpretacije rezultata i trebaju poučiti pacijente kako se p
Abstract (english) Given the fact that biotin is increasingly used in multivitamin supplements, biotin-based skin, hair and nail products, as well as a
medication for treatment of progressive multiple sclerosis, medical biochemistry laboratory professionals and physicians should be
aware that biotin can affect results in immunochemical analyses that use biotin and the streptavidin-biotin interaction in their platform.
Biotin affects the results in immunochemical analysis in two ways: in competitive tests it causes false positive results, and in sandwich
tests it causes false low results. The aim of this paper was to examine the impact of biotin on five analytes (vitamin D, CEA, CA 19-
9, AFP and vitamin B12) when administered at a dose of 5 mg. The research was designed in such a way to measure the concentrations
of analytes in serum two times (before taking biotin and three hours after taking biotin). Twelve subjects participated in the research
(six male and six female) and biotin concentrations were determined with the Cobas e601 immunoassay analyser using the
electrochemiluminescence immunoassay (ECLIA) method. The investigation showed that 5 mg of biotin did not interfere in any of
twelve subjects with CEA, CA 19-9, AFP and B12, and in terms of vitamin D, it interfered with one out of twelve subjects. If biotin
is taken at doses much higher than 5 mg (therapeutic doses for multiple sclerosis range from 100 to 300 mg), it will interfere with all
analytes. There are four methods that clinical laboratories use in order to avoid biotin interference. These are the use of a test platform
that does not use biotin in the design of the assay, serial dilution of the sample, waiting long enough for the biotin to be removed from
the body and pre-treatment of samples with streptavidin-coated microparticles for the removal of biotin present in the samples.
Clinical laboratory professionals should be careful when interpreting results and should educate patients on how to prepare for
immunochemical analysis if they take biotin and thus minimise errors in lab results.
Keywords
biotin
interferencija
imunokemijska analiza
Keywords (english)
biotin
interference
immunoassay
Language croatian
URN:NBN urn:nbn:hr:163:563387
Study programme Title: Medical biochemistry Study programme type: university Study level: integrated undergraduate and graduate Academic / professional title: magistar/magistra medicinske biokemije (magistar/magistra medicinske biokemije)
Type of resource Text
File origin Born digital
Access conditions Open access
Terms of use
Created on 2020-02-13 09:35:18